key: cord-0937911-yv5yz261 authors: Lu, Hongzhou; Stratton, Charles W.; Tang, Yi‐Wei title: An Evolving Approach to the Laboratory Assessment of COVID‐19 date: 2020-04-29 journal: J Med Virol DOI: 10.1002/jmv.25954 sha: 9298a0fc935dcacf88ec7ca9acf717c6f55ed7f8 doc_id: 937911 cord_uid: yv5yz261 As the COVID‐19 outbreak has evolved in each country, the approach to the laboratory assessment of SARS‐CoV‐2 infection has had to evolve as well. This review addresses the evolving approach to the laboratory assessment of COVID‐19 and discusses how algorithms for testing have been driven, in part, by the demand for testing overwhelming the capacity to accomplish such testing. This review focused on testing in the United States as this testing is evolving whereas in China and other countries such as South Korea testing is widely available and includes both molecular testing for SARS‐CoV‐2 as well as serological testing using both ELISA methodology and lateral flow immunoassay methodology. Although commercial testing systems are becoming available, there will likely be insufficient numbers of such tests due to high demand. Serological testing will be the next testing issue as the COVID‐19 begins to subside. This will allow immunity testing as well as will allow the parameters of the COVID‐19 outbreak to be defined. This article is protected by copyright. All rights reserved. Rapid, commercial COVID-19 testing methods as well as algorithms for their use are being developed and implemented throughout the words. These will assist in the control and final resolution of this outbreak. As the COVID-19 public health emergency rapidly evolves country by country, the responses in each country must meet the emerging needs. But a common factor for every country is the need for widespread testing at the level of small communities 6 . As the COVID-19 outbreak begins to subside, serological testing will be needed to determine who is likely to be immune and thus might be able to return to work, particularly if such work is a critical occupation. Serological testing will also be needed to determine the epidemiological characteristics such as the true case fatality rate. Wide availability at the community level for commercial molecular testing instruments that can use approved SARS-CoV-2 test kits will be absolutely critical for controlling this COVID-19 outbreak. As many hospitals and clinics already are using such instruments, they would only need to verify the SARS-CoV-2 testing on their instruments to be able to offer such testing at the local community level. In the United States, this will require the FDA approval for "emergency use authorization" (EUA) for in vitro diagnostic use tests. At the time of writing, 39 kits, most of them are commercial except for the one from the US CDC and the NY State of Health, received EUA clearance (https://www.fda.gov/medical-devices/emergency-situationsmedical-devices/emergency-use-authorizations#coronavirus2019. Accessed 18 April 2020). However, the demand for these commercial COVID-19 devices could easily exceed the capability of their respective manufacturers to supply a large initial demand. This article is protected by copyright. All rights reserved. Random-Access, Integrated, Sealed Devices. Many of these random-access devices are real-time RT-PCR-based procedures which do include a separate nucleic acid extraction procedure before the procedure of simultaneous nucleic acid amplification and detection. However, several commercial testing instruments now offer "sealed" systems that integrate nucleic acid extraction, amplification and detection; once the clinical sample in universal transport medium is loaded into the instrument's cartridge in a biosafety cabinet, the cartridge is "sealed" [7] [8] [9] [10] Because such large scale, high trough put molecular testing instruments use batched testing, this testing takes longer. Some medical centers are using random-access point of care COVID-19 testing kits for priority testing while using the slower large scale, high throughput COVID-19 testing platforms for epidemiological purposes. This article is protected by copyright. All rights reserved. Access to COVID-19 testing in many countries, including the United States, continues to be inadequate, which greatly impedes the ability of clinicians and public health authorities to accurately determine and track the prevalence and transmissibility of this outbreak. Moreover, inadequate testing capabilities and/or testing delays also may hamper the clinicians' ability to appropriately identify, isolate, and treat these patients. One factor that has already been noted to limit the ability of COVID-19 testing is the scarcity of many testing consumables. A number of these scarcities will be discussed in the following subsections. collected and transported to the laboratory in universal/viral transport medium 17-20 . It is hard to imagine that these swabs, viral transport media, screw-cap tubes, plastic bags to transport the specimens, cold packs to cool the specimen, and styrofoam containers would become scarce, but this is happening in the United States as COVID-19 testing efforts are increasing. Several medical centers have resorted to making their own viral transport medium to meet this need. Saline, phosphate buffered saline and minimum essential medium were even evaluated as potential alternatives to viral transport media for SARS-CoV-2 testing 21 . Needless to say, this outbreak was not anticipated, and manufacturers of these specimen collection items require time to increase their production. Readers are suggested to follow CLSI M40 (Quality Control of Microbiological Transport Systems; Approved Standard) to validate different collection matrixes. This article is protected by copyright. All rights reserved. A recognized limitation of the use of OP or NP swabs for collecting upper respiratory tract specimens for COVID-19 molecular testing is that false-negative results of these initial real-time RT-PCR assays are known to occur 22, 23 (https://doi.org/10.1101/2020.04. 16 become scarce as they have been consumed in early COVID-19 testing. Some laboratories have had to validate three different DNA polymerases mix reagents and three different extraction mix reagents so that their testing methods could easily shift and use whatever reagents are currently available. Because availability of COVID-19 diagnostic testing is limited, the Infectious Diseases Society of America (IDSA) had developed a testing algorithm to help clinicians test wisely as well as for the laboratory reporting of these results (https://www.idsociety.org/globalassets/idsa/public-health/covid-19-idsa-testingintro.pdf. Accessed 26 March 2020). Importantly, the IDSA has recommended that the CDC should publicly disclose the number of cases tested in any one location or state in order to better gauge the significance of the number of positive results. The number of positive results in locations or states that have few or no reported cases may signify low or no prevalence of COVID-19 or may mean that such low positive results are due to undertesting. This, in turn, will determine how aggressive testing needs to be in these locations or states. At the time of writing, the IDSA recommends a four-tier approach to COVID-19 diagnostic testing as shown in Table 1 . Accessed 6 April 2020) 38, 39 . Serology can be used to contact tracing, which is especially useful during current shortage of molecular assays. Serology results can be used in COVID-19 case confirmation when viral RNA-negative patients presenting late in the illness 40 . Beyond diagnosis, serology results may be used to guide returnto-work decision 41 . However, antibody detection measures past exposure to SARS-CoV-2 and another production is host dependent and takes time. As a natural delay, antibody testing is not useful in the setting of an acute illness 22, 23 . A recent study validated the VivaDiag IgM/IgG Rapid Test 37 in acute patients referring to emergency room department in Italy. The sensitivity and specificity were 18.4% and 91.7%, indicating the serology This article is protected by copyright. All rights reserved. assay should be avoided for triage of patients with suspected COVID-19 26 . Possible explanations included the low antibody titers or delayed humoral responses in patients with SARS-CoV-2 infections 42 . A recent study revealed that the presence of anti-SARS-CoV-2 IgG did not start till the illness day 11 and post-exposure 18-21 days 43 . Although unlikely to be very useful for the diagnosis of acute COVID-19, serology, especially ELISA-based ones, will be very useful for defining immunity as well as better characterizing certain parameters such as the true fatality rate. Result interpretation in the clinical setting in combination of molecular results is listed in Table 2 . As the COVID-10 outbreak has evolved, so has the approach to SARS-CoV-2 testing. Availability of molecular testing for COVID-19 has been limited in many areas due to a lack of consumable reagents. This has required testing algorithms. Fortunately, random-access point-of-care devices will soon be able to bring molecular testing to small communities. Initial availability of these kits may be limited due to a high demand. As these instruments become available, this capability combined with ELISA-based serological testing for immunity will further assist with the resolution of this outbreak. Concept forming: HL, and YWT. Content contribution: HL, CWS and YWT. Writing: This article is protected by copyright. All rights reserved. COVID-19: towards controlling of a pandemic Novel Coronavirus and Old Lessons -Preparing the Health System for the Pandemic The Wuhan SARS-CoV-2-What's next for China Outbreak of pneumonia of unknown etiology in The mystery and the miracle The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Audio Interview: Emerging Tools in the Fight against Covid-19 This article is protected by copyright. All rights reserved Integrated Amplification Microarrays for Infectious Disease Diagnostics. Microarrays (Basel) Comparison of the Luminex xTAG RVP Fast assay and the Idaho Technology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital Parallel Validation of Three Molecular Devices for Simultaneous Detection and Identification of Influenza A and B and Respiratory Syncytial Viruses Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 COVID-19 and the Risk to Health Care Workers: A Case Report Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system All rights reserved. Respiratory Pathogen Panel Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load Multicenter Evaluation of NeuMoDx Group B Streptococcus Assay on the NeuMoDx 288 Molecular System Comparison of Six Sample-to-Answer Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Amplification Assays Using Respiratory Specimens from Children Surveillance of Acute Respiratory Infections Using Community-Submitted Symptoms and Specimens for Molecular Diagnostic Testing Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by realtime reverse transcription-PCR assays Additional molecular testing of saliva specimens improves the detection of respiratory viruses Evaluation of saline, phosphate buffered saline and minimum essential medium as potential alternatives to viral transport media for SARS-CoV-2 testing Laboratory diagnosis of emerging human coronavirus infections -the state of the art The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges This article is protected by copyright. All rights reserved Consistent detection of 2019 novel coronavirus in saliva Comparison of the new fully automated extraction platform eMAG to the MagNA PURE 96 and the well-established easyMAG for detection of common human respiratory viruses Performance of VivaDiagTM COVID-19 Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department Multicenter comparative evaluation of five commercial methods for toxoplasma DNA extraction from amniotic fluid Virus inactivation by nucleic acid extraction reagents The effect of a non-denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus Developing antibody tests for SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Serological assays for emerging coronaviruses: challenges and pitfalls Structural insights into coronavirus entry Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes Lateral flow assays Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Report from the American Society for Microbiology COVID-19 International Summit Virological assessment of hospitalized patients with COVID-2019 A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic This article is protected by copyright. All rights reserved • Critically ill patients receiving ICU level care with unexplained viral pneumoniae or respiratory failure, regardless of travel history or close contact with suspected or confirmed COVID-1 patients; • Any person, including health care workers, with fever or signs/symptoms of a lower respiratory tract illness and close contact with a laboratory-confirmed COVID-19 patient within 14 days of symptom onset (including all residents at a long-term care facility that has a laboratory-confirmed COVID-19 case]; • Any person, including health care workers, with fever or signs/symptoms of a lower respiratory tract illness and a history of travel within 14 days of symptom onset to geographical regions where sustained community transmission has been identified; (iv) Individuals with fever or signs/symptoms of a lower respiratory tract illness who are also immunosuppressed (including patients with HIV), elderly, or have underlying chronic health conditions; • Individuals with fever or signs/symptoms of a lower respiratory tract illness who are critical to pandemic response, including health care workers, public health officials and other essential leaders. • Hospitalized (non-ICU) patients and long-term care residents with unexplained fever and signs/symptoms of a lower respiratory tract illness. The number of confirmed COVID-19 cases in the community should be considered. As testing becomes more widely available, routine testing of hospitalized patients may be important for infection prevention and management of discharge. • Patients in outpatient settings who meet the criteria for influenza testing. This includes individuals with co-morbid conditions including diabetes, COPD, congestive heart failure, age >50, immunocompromised hosts among others. Given limited available data, testing of pregnant women and symptomatic children with similar risk factors for complications is encouraged. The number of confirmed COVID-19 cases in the community should be considered.